Citigroup
ZYNE

Citigroup’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Citigroup’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100
Closed -$53 – 5977
2022
Q4 		$53 Buy
+100
New +$63 ﹤0.01% 5666
2022
Q3 		– Sell
-138
Closed – – 6508
2022
Q2 		$0 Buy
+138
New +$176 ﹤0.01% 6815
2021
Q3 		– Sell
-500
Closed -$3K – 6428
2021
Q2 		$3K Hold
500
– – ﹤0.01% 5947
2021
Q1 		$2K Sell
500
-500
-50% -$2.27K ﹤0.01% 6067
2020
Q4 		$3K Hold
1,000
– – ﹤0.01% 7219
2020
Q3 		$3K Sell
1,000
-1,707
-63% -$6.27K ﹤0.01% 7252
2020
Q2 		$9K Sell
2,707
-4,499
-62% -$21.3K ﹤0.01% 7113
2020
Q1 		$28K Buy
7,206
+266
+4% +$1.24K ﹤0.01% 6465
2019
Q4 		$42K Buy
6,940
+3,352
+93% +$22.9K ﹤0.01% 6456
2019
Q3 		$27K Buy
3,588
+3,068
+590% +$34.6K ﹤0.01% 6552
2019
Q2 		$7K Buy
520
+20
+4% +$231 ﹤0.01% 7406
2019
Q1 		$3K Hold
500
– – ﹤0.01% 7502
2018
Q4 		$1K Hold
500
– – ﹤0.01% 7614
2018
Q3 		$4K Hold
500
– – ﹤0.01% 7537
2018
Q2 		$5K Sell
500
-12
-2% -$123 ﹤0.01% 7367
2018
Q1 		$4K Sell
512
-173
-25% -$1.87K ﹤0.01% 7265
2017
Q4 		$9K Sell
685
-4,227
-86% -$48.4K ﹤0.01% 7088
2017
Q3 		$41K Sell
4,912
-216,786
-98% -$2.29M ﹤0.01% 6101
2017
Q2 		$3.76M Buy
221,698
+220,068
+13,501% +$4.38M ﹤0.01% 1960
2017
Q1 		$33K Buy
1,630
+630
+63% +$12.5K ﹤0.01% 5975
2016
Q4 		$16K Hold
1,000
– – ﹤0.01% 6613
2016
Q3 		$13K Buy
+1,000
New +$9.5K ﹤0.01% 6422
2016
Q2 		– Sell
-2,562
Closed -$24K – 7533
2016
Q1 		$24K Buy
2,562
+1,493
+140% +$12K ﹤0.01% 6474
2015
Q4 		$10K Buy
+1,069
New +$14.1K ﹤0.01% 6828

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's ZYNE Position: Q1 2023 in Review

Citigroup sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2023, closing a stake of 100 shares — an estimated $53 sold.

Citigroup first reported a position in ZYNE in Q4 2015 and held it in 24 quarters. The position peaked at $3.76M in Q2 2017. 44 funds tracked by Wall St. Rank hold ZYNE as of Q1 2023.

  • Citigroup reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2023 after selling out during the quarter.
  • Citigroup sold 100 Zynerba Pharmaceuticals, Inc shares in Q1 2023, an estimated $53.
  • Citigroup first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2015 and held it in 24 quarters.
  • Citigroup's Zynerba Pharmaceuticals, Inc position peaked at $3.76M in Q2 2017.
  • 44 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2023.

Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.